TheraRadar

SymBio

Pre-Approval PRO BETA
22
Total Trials
3
Phase 3
10
Phase 2
2
Recruiting
168
Score

Pipeline by Phase

Phase 3
3
Phase 2
10
Phase 1
11

Therapeutic Focus

Myelodysplastic Syndrome Adenovirus Infections Non-Hodgkin's Lymphoma Follicular Lymphoma Relapsed or Refractory Lymphoma Including ENKL

Clinical Trials (22)

NCT07387367 Phase 3 RECRUITING

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Started: 3/17/2026

NCT03372837 Phase 3 COMPLETED

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Started: 1/15/2018

NCT03005899 Phase 3 TERMINATED

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Started: 11/21/2016

NCT04706923 Phase 2 RECRUITING

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Started: 8/16/2021

NCT05511779 Phase 2 TERMINATED

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

Started: 10/14/2022

NCT02042911 Phase 2 COMPLETED

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Started: 1/1/2013

NCT01718691 Phase 2 COMPLETED

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Started: 11/1/2011

NCT01849848 Phase 2 COMPLETED

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Started: 11/1/2011

NCT01700140 Phase 2 COMPLETED

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Started: 5/1/2011

NCT01118845 Phase 2 COMPLETED

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Started: 4/1/2010

NCT01179490 Phase 2 TERMINATED

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Started: 9/1/2010

NCT06761677 Phase 1 SUSPENDED

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Started: 6/9/2025

NCT03900377 Phase 1 COMPLETED

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Started: 4/1/2019

NCT02014051 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Started: 3/1/2013

NCT01700335 Phase 1 COMPLETED

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Started: 6/1/2012

NCT02783547 Phase 1 WITHDRAWN

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Started: 12/1/2015

NCT03495167 Phase 1 COMPLETED

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Started: 10/6/2017

NCT00794638 Phase 1 COMPLETED

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Started: 11/1/2008

NCT03604679 Phase 1 COMPLETED

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Started: 5/24/2018

NCT04542252 Phase 1 COMPLETED

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Started: 11/9/2020

NCT02000154 Phase 1 COMPLETED

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Started: 12/1/2014

NCT02002936 Phase 1 COMPLETED

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Started: 8/1/2013

Drug Candidates

cidofovir Brincidofovir BCV SyB L-0501RI Rituximab SyB C-1101 SyB L-1101 SyB C-1101 and Azacytidine SyB P-1501 SyB P-1501 placebo
Activity Status: Active
Last Trial Started: 3/17/2026
Last Trial Ended: 4/13/2023
Trials (12 months): 2
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.